

# Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2022

<https://marketpublishers.com/r/G452EA284460EN.html>

Date: January 2023

Pages: 300

Price: US\$ 3,450.00 (Single User License)

ID: G452EA284460EN

## Abstracts

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028. This research study of Chemotherapy Induced Peripheral Neuropathy Treatment involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.

Scope of the Chemotherapy Induced Peripheral Neuropathy Treatment Market  
The Chemotherapy Induced Peripheral Neuropathy Treatment Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage. The study includes drivers and restraints for Chemotherapy Induced Peripheral Neuropathy Treatment Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting the growth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Chemotherapy Induced Peripheral Neuropathy Treatment Market helps user to make precise decision in order to expand their market presence and increase market share.

Impact of COVID-19 on Chemotherapy Induced Peripheral Neuropathy Treatment Market

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Chemotherapy Induced Peripheral Neuropathy Treatment market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation  
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;

By Type, Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into:

- Calcium Channel ?2-delta Ligands
- Antidepressants
- Opioids
- Others

By Application, Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into:

- Platinum Agents
- Taxanes
- Vinca Alkaloids
- Others

Regional Analysis:

- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
- South America (Brazil, Argentina, Rest of SA)
- Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)

Competitive Landscape:

Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market. The Chemotherapy Induced Peripheral Neuropathy Treatment market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Chemotherapy Induced Peripheral Neuropathy Treatment market.

Top Key Players Covered in Chemotherapy Induced Peripheral Neuropathy Treatment market are:

Asahi Kasei Pharma Corp  
Nemus Bioscience Inc  
DermaXon LLC  
Kineta Inc  
PeriphaGen  
Krenitsky Pharmaceuticals Inc  
PledPharma  
MAKScientific LLC  
Aptinyx Inc  
Metys Pharmaceuticals AG  
Regenacy Pharmaceuticals  
Sova Pharmaceuticals Inc  
Apexian Pharma  
WinSanTor

Objective to buy this Report:

1. Chemotherapy Induced Peripheral Neuropathy Treatment analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Chemotherapy Induced Peripheral Neuropathy Treatment market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.

## Contents

### **CHAPTER 1: INTRODUCTION**

- 1.1 RESEARCH OBJECTIVES
- 1.2 RESEARCH METHODOLOGY
- 1.3 RESEARCH PROCESS
- 1.4 SCOPE AND COVERAGE
  - 1.4.1 MARKET DEFINITION
  - 1.4.2 KEY QUESTIONS ANSWERED
- 1.5 MARKET SEGMENTATION

### **CHAPTER 2: EXECUTIVE SUMMARY**

### **CHAPTER 3: GROWTH OPPORTUNITIES BY SEGMENT**

- 3.1 BY TYPE
- 3.2 BY APPLICATION

### **CHAPTER 4: MARKET LANDSCAPE**

- 4.1 PORTER'S FIVE FORCES ANALYSIS
  - 4.1.1 BARGAINING POWER OF SUPPLIER
  - 4.1.2 THREAT OF NEW ENTRANTS
  - 4.1.3 THREAT OF SUBSTITUTES
  - 4.1.4 COMPETITIVE RIVALRY
  - 4.1.5 BARGAINING POWER AMONG BUYERS
- 4.2 INDUSTRY VALUE CHAIN ANALYSIS
- 4.3 MARKET DYNAMICS
  - 4.3.1 DRIVERS
  - 4.3.2 RESTRAINTS
  - 4.3.3 OPPORTUNITIES
  - 4.5.4 CHALLENGES
- 4.4 PESTLE ANALYSIS
- 4.5 TECHNOLOGICAL ROADMAP
- 4.6 REGULATORY LANDSCAPE
- 4.7 SWOT ANALYSIS
- 4.8 PRICE TREND ANALYSIS
- 4.9 PATENT ANALYSIS

- 4.10 ANALYSIS OF THE IMPACT OF COVID-19
  - 4.10.1 IMPACT ON THE OVERALL MARKET
  - 4.10.2 IMPACT ON THE SUPPLY CHAIN
  - 4.10.3 IMPACT ON THE KEY MANUFACTURERS
  - 4.10.4 IMPACT ON THE PRICING

## **CHAPTER 5: CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET BY TYPE**

- 5.1 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
- 5.2 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW
- 5.3 CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS
  - 5.3.1 INTRODUCTION AND MARKET OVERVIEW
  - 5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
  - 5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
  - 5.3.4 CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS: GEOGRAPHIC SEGMENTATION
- 5.4 ANTIDEPRESSANTS
  - 5.4.1 INTRODUCTION AND MARKET OVERVIEW
  - 5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
  - 5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
  - 5.4.4 ANTIDEPRESSANTS: GEOGRAPHIC SEGMENTATION
- 5.5 OPIOIDS
  - 5.5.1 INTRODUCTION AND MARKET OVERVIEW
  - 5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
  - 5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
  - 5.5.4 OPIOIDS: GEOGRAPHIC SEGMENTATION
- 5.6 OTHERS
  - 5.6.1 INTRODUCTION AND MARKET OVERVIEW
  - 5.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
  - 5.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
  - 5.6.4 OTHERS: GEOGRAPHIC SEGMENTATION

## **CHAPTER 6: CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET BY APPLICATION**

- 6.1 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE

## 6.2 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW

### 6.3 PLATINUM AGENTS

#### 6.3.1 INTRODUCTION AND MARKET OVERVIEW

#### 6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

#### 6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

#### 6.3.4 PLATINUM AGENTS: GEOGRAPHIC SEGMENTATION

### 6.4 TAXANES

#### 6.4.1 INTRODUCTION AND MARKET OVERVIEW

#### 6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

#### 6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

#### 6.4.4 TAXANES: GEOGRAPHIC SEGMENTATION

### 6.5 VINCA ALKALOIDS

#### 6.5.1 INTRODUCTION AND MARKET OVERVIEW

#### 6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

#### 6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

#### 6.5.4 VINCA ALKALOIDS: GEOGRAPHIC SEGMENTATION

### 6.6 OTHERS

#### 6.6.1 INTRODUCTION AND MARKET OVERVIEW

#### 6.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

#### 6.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

#### 6.6.4 OTHERS: GEOGRAPHIC SEGMENTATION

## **CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS**

### 7.1 COMPETITIVE LANDSCAPE

#### 7.1.1 COMPETITIVE POSITIONING

#### 7.1.2 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT SALES AND MARKET SHARE BY PLAYERS

#### 7.1.3 INDUSTRY BCG MATRIX

#### 7.1.4 HEAT MAP ANALYSIS

#### 7.1.5 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)

#### 7.1.6 TOP 5 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT PLAYERS MARKET SHARE

#### 7.1.7 MERGERS AND ACQUISITIONS

#### 7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS

### 7.2 ASAHI KASEI PHARMA CORP

#### 7.2.1 COMPANY OVERVIEW

- 7.2.2 KEY EXECUTIVES
- 7.2.3 COMPANY SNAPSHOT
- 7.2.4 OPERATING BUSINESS SEGMENTS
- 7.2.5 PRODUCT PORTFOLIO
- 7.2.6 BUSINESS PERFORMANCE
- 7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
- 7.2.8 SWOT ANALYSIS
- 7.3 NEMUS BIOSCIENCE INC
- 7.4 DERMAXON LLC
- 7.5 KINETA INC
- 7.6 PERIPHAGEN
- 7.7 KRENITSKY PHARMACEUTICALS INC
- 7.8 PLEDPHARMA
- 7.9 MAKSCIENTIFIC LLC
- 7.10 APTINYX INC
- 7.11 METYS PHARMACEUTICALS AG
- 7.12 REGENACY PHARMACEUTICALS
- 7.13 SOVA PHARMACEUTICALS INC
- 7.14 APEXIAN PHARMA
- 7.15 WINSANTOR

## **CHAPTER 8: GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028**

- 8.1 MARKET OVERVIEW
- 8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
  - 8.2.1 CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS
  - 8.2.2 ANTIDEPRESSANTS
  - 8.2.3 OPIOIDS
  - 8.2.4 OTHERS
- 8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
  - 8.3.1 PLATINUM AGENTS
  - 8.3.2 TAXANES
  - 8.3.3 VINCA ALKALOIDS
  - 8.3.4 OTHERS

## **CHAPTER 9: NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028**



9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

9.2 IMPACT OF COVID-19

9.3 KEY PLAYERS

9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE

9.4.1 CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS

9.4.2 ANTIDEPRESSANTS

9.4.3 OPIOIDS

9.4.4 OTHERS

9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION

9.5.1 PLATINUM AGENTS

9.5.2 TAXANES

9.5.3 VINCA ALKALOIDS

9.5.4 OTHERS

9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY

9.6.1 U.S.

9.6.2 CANADA

9.6.3 MEXICO

## **CHAPTER 10: EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028**

10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

10.2 IMPACT OF COVID-19

10.3 KEY PLAYERS

10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE

10.4.1 CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS

10.4.2 ANTIDEPRESSANTS

10.4.3 OPIOIDS

10.4.4 OTHERS

10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION

10.5.1 PLATINUM AGENTS

10.5.2 TAXANES

10.5.3 VINCA ALKALOIDS

10.5.4 OTHERS

10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY

10.6.1 GERMANY



- 10.6.2 U.K.
- 10.6.3 FRANCE
- 10.6.4 ITALY
- 10.6.5 RUSSIA
- 10.6.6 SPAIN
- 10.6.7 REST OF EUROPE

## **CHAPTER 11: ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028**

- 11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 11.2 IMPACT OF COVID-19
- 11.3 KEY PLAYERS
- 11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
  - 11.4.1 CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS
  - 11.4.2 ANTIDEPRESSANTS
  - 11.4.3 OPIOIDS
  - 11.4.4 OTHERS
- 11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
  - 11.5.1 PLATINUM AGENTS
  - 11.5.2 TAXANES
  - 11.5.3 VINCA ALKALOIDS
  - 11.5.4 OTHERS
- 11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
  - 11.6.1 CHINA
  - 11.6.2 INDIA
  - 11.6.3 JAPAN
  - 11.6.4 SINGAPORE
  - 11.6.5 AUSTRALIA
  - 11.6.6 NEW ZEALAND
  - 11.6.7 REST OF APAC

## **CHAPTER 12: MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028**

- 12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

- 12.2 IMPACT OF COVID-19
- 12.3 KEY PLAYERS
- 12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
  - 12.4.1 CALCIUM CHANNEL  $\gamma$ -2-DELTA LIGANDS
  - 12.4.2 ANTIDEPRESSANTS
  - 12.4.3 OPIOIDS
  - 12.4.4 OTHERS
- 12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
  - 12.5.1 PLATINUM AGENTS
  - 12.5.2 TAXANES
  - 12.5.3 VINCA ALKALOIDS
  - 12.5.4 OTHERS
- 12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
  - 12.6.1 TURKEY
  - 12.6.2 SAUDI ARABIA
  - 12.6.3 IRAN
  - 12.6.4 UAE
  - 12.6.5 AFRICA
  - 12.6.6 REST OF MEA

## **CHAPTER 13: SOUTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028**

- 13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 13.2 IMPACT OF COVID-19
- 13.3 KEY PLAYERS
- 13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
  - 13.4.1 CALCIUM CHANNEL  $\gamma$ -2-DELTA LIGANDS
  - 13.4.2 ANTIDEPRESSANTS
  - 13.4.3 OPIOIDS
  - 13.4.4 OTHERS
- 13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
  - 13.5.1 PLATINUM AGENTS
  - 13.5.2 TAXANES
  - 13.5.3 VINCA ALKALOIDS
  - 13.5.4 OTHERS

## 13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY

13.6.1 BRAZIL

13.6.2 ARGENTINA

13.6.3 REST OF SA

## **CHAPTER 14 INVESTMENT ANALYSIS**

## **CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY

TABLE 002. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET BARGAINING POWER OF SUPPLIERS

TABLE 003. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET BARGAINING POWER OF CUSTOMERS

TABLE 004. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET COMPETITIVE RIVALRY

TABLE 005. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET THREAT OF NEW ENTRANTS

TABLE 006. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET THREAT OF SUBSTITUTES

TABLE 007. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET BY TYPE

TABLE 008. CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS MARKET OVERVIEW (2016-2028)

TABLE 009. ANTIDEPRESSANTS MARKET OVERVIEW (2016-2028)

TABLE 010. OPIOIDS MARKET OVERVIEW (2016-2028)

TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)

TABLE 012. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET BY APPLICATION

TABLE 013. PLATINUM AGENTS MARKET OVERVIEW (2016-2028)

TABLE 014. TAXANES MARKET OVERVIEW (2016-2028)

TABLE 015. VINCA ALKALOIDS MARKET OVERVIEW (2016-2028)

TABLE 016. OTHERS MARKET OVERVIEW (2016-2028)

TABLE 017. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE (2016-2028)

TABLE 018. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY APPLICATION (2016-2028)

TABLE 019. N CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY COUNTRY (2016-2028)

TABLE 020. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE (2016-2028)

TABLE 021. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY APPLICATION (2016-2028)

TABLE 022. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY

TREATMENT MARKET, BY COUNTRY (2016-2028)

TABLE 023. ASIA PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE (2016-2028)

TABLE 024. ASIA PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY APPLICATION (2016-2028)

TABLE 025. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY COUNTRY (2016-2028)

TABLE 026. MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE (2016-2028)

TABLE 027. MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY APPLICATION (2016-2028)

TABLE 028. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY COUNTRY (2016-2028)

TABLE 029. SOUTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE (2016-2028)

TABLE 030. SOUTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY APPLICATION (2016-2028)

TABLE 031. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, BY COUNTRY (2016-2028)

TABLE 032. ASAHI KASEI PHARMA CORP: SNAPSHOT

TABLE 033. ASAHI KASEI PHARMA CORP: BUSINESS PERFORMANCE

TABLE 034. ASAHI KASEI PHARMA CORP: PRODUCT PORTFOLIO

TABLE 035. ASAHI KASEI PHARMA CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 035. NEMUS BIOSCIENCE INC: SNAPSHOT

TABLE 036. NEMUS BIOSCIENCE INC: BUSINESS PERFORMANCE

TABLE 037. NEMUS BIOSCIENCE INC: PRODUCT PORTFOLIO

TABLE 038. NEMUS BIOSCIENCE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 038. DERMAXON LLC: SNAPSHOT

TABLE 039. DERMAXON LLC: BUSINESS PERFORMANCE

TABLE 040. DERMAXON LLC: PRODUCT PORTFOLIO

TABLE 041. DERMAXON LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 041. KINETA INC: SNAPSHOT

TABLE 042. KINETA INC: BUSINESS PERFORMANCE

TABLE 043. KINETA INC: PRODUCT PORTFOLIO

TABLE 044. KINETA INC: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 044. PERIPHAGEN: SNAPSHOT

TABLE 045. PERIPHAGEN: BUSINESS PERFORMANCE

TABLE 046. PERIPHAGEN: PRODUCT PORTFOLIO  
TABLE 047. PERIPHAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 047. KRENITSKY PHARMACEUTICALS INC: SNAPSHOT  
TABLE 048. KRENITSKY PHARMACEUTICALS INC: BUSINESS PERFORMANCE  
TABLE 049. KRENITSKY PHARMACEUTICALS INC: PRODUCT PORTFOLIO  
TABLE 050. KRENITSKY PHARMACEUTICALS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 050. PLEDPHARMA: SNAPSHOT  
TABLE 051. PLEDPHARMA: BUSINESS PERFORMANCE  
TABLE 052. PLEDPHARMA: PRODUCT PORTFOLIO  
TABLE 053. PLEDPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 053. MAKSCIENTIFIC LLC: SNAPSHOT  
TABLE 054. MAKSCIENTIFIC LLC: BUSINESS PERFORMANCE  
TABLE 055. MAKSCIENTIFIC LLC: PRODUCT PORTFOLIO  
TABLE 056. MAKSCIENTIFIC LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 056. APTINYX INC: SNAPSHOT  
TABLE 057. APTINYX INC: BUSINESS PERFORMANCE  
TABLE 058. APTINYX INC: PRODUCT PORTFOLIO  
TABLE 059. APTINYX INC: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 059. METYS PHARMACEUTICALS AG: SNAPSHOT  
TABLE 060. METYS PHARMACEUTICALS AG: BUSINESS PERFORMANCE  
TABLE 061. METYS PHARMACEUTICALS AG: PRODUCT PORTFOLIO  
TABLE 062. METYS PHARMACEUTICALS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 062. REGENACY PHARMACEUTICALS: SNAPSHOT  
TABLE 063. REGENACY PHARMACEUTICALS: BUSINESS PERFORMANCE  
TABLE 064. REGENACY PHARMACEUTICALS: PRODUCT PORTFOLIO  
TABLE 065. REGENACY PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 065. SOVA PHARMACEUTICALS INC: SNAPSHOT  
TABLE 066. SOVA PHARMACEUTICALS INC: BUSINESS PERFORMANCE  
TABLE 067. SOVA PHARMACEUTICALS INC: PRODUCT PORTFOLIO  
TABLE 068. SOVA PHARMACEUTICALS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 068. APEXIAN PHARMA: SNAPSHOT  
TABLE 069. APEXIAN PHARMA: BUSINESS PERFORMANCE  
TABLE 070. APEXIAN PHARMA: PRODUCT PORTFOLIO  
TABLE 071. APEXIAN PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS  
TABLE 071. WINSANTOR: SNAPSHOT

TABLE 072. WINSANTOR: BUSINESS PERFORMANCE

TABLE 073. WINSANTOR: PRODUCT PORTFOLIO

TABLE 074. WINSANTOR: KEY STRATEGIC MOVES AND DEVELOPMENTS



## List Of Figures

### LIST OF FIGURES

- FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
- FIGURE 002. SCOPE OF THE STUDY
- FIGURE 003. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY REGIONS
- FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 005. BARGAINING POWER OF SUPPLIERS
- FIGURE 006. COMPETITIVE RIVALRY
- FIGURE 007. THREAT OF NEW ENTRANTS
- FIGURE 008. THREAT OF SUBSTITUTES
- FIGURE 009. VALUE CHAIN ANALYSIS
- FIGURE 010. PESTLE ANALYSIS
- FIGURE 011. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY TYPE
- FIGURE 012. CALCIUM CHANNEL  $\alpha$ 2-DELTA LIGANDS MARKET OVERVIEW (2016-2028)
- FIGURE 013. ANTIDEPRESSANTS MARKET OVERVIEW (2016-2028)
- FIGURE 014. OPIOIDS MARKET OVERVIEW (2016-2028)
- FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
- FIGURE 016. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY APPLICATION
- FIGURE 017. PLATINUM AGENTS MARKET OVERVIEW (2016-2028)
- FIGURE 018. TAXANES MARKET OVERVIEW (2016-2028)
- FIGURE 019. VINCA ALKALOIDS MARKET OVERVIEW (2016-2028)
- FIGURE 020. OTHERS MARKET OVERVIEW (2016-2028)
- FIGURE 021. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 022. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 023. ASIA PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 024. MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 025. SOUTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)

## I would like to order

Product name: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2022

Product link: <https://marketpublishers.com/r/G452EA284460EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G452EA284460EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

